| Australia | 6wk, 4, 6, 12, 18m | 3+1 hexa | ✔ universal | 2+1 PCV20 (3+1 Indigenous) | ✔ | ◑ Indigenous; SA/QLD/NT universal | ✔ ACWY 12m | ✔ MMRV 18m | ◑ Indigenous (4 states) | ✘ | ✔ | Maternal Abrysvo ✔ + state nirsevimab ◑ | Incentive (No Jab No Pay/Play) |
| New Zealand | 6wk, 3, 5, 12, 15m | 3+0 hexa + Hib 15m | ◑ HBsAg+ mothers | 2+1 PCV13 | ✔ | ✔ 3, 5, 12m (since 2023) | ✘ | ✔ 15m | ✘ | ◑ | ✘ (risk only) | ? none national | Voluntary |
| UK | 8, 12, 16wk, 12, 18m | 3+1 hexa (18m booster from 2026) | ◑ selective | 1+1 PCV13 | ✔ | ✔ 2+1 | ✘ (Hib/MenC dropped 2025) | ✔ MMRV 12 & 18m (from Jan 2026) | ✘ | ◑ | ✘ (LAIV from 2y) | Maternal Abrysvo ✔ | Voluntary |
| Ireland | 2, 4, 6, 12, 13m | 3+0 hexa | ◑ | 2+1 | ✔ | ✔ | ✔ | ? | ✘ | ✘ (stopped 2015) | ✘ (LAIV 2y+) | Nirsevimab ✔ | Voluntary |
| United States (Jan 2026 CDC) | birth, 2, 4, 6, 12–18m | 3+1 DTaP | ◑ only if mother HBsAg+/unknown (universal recommendation dropped Dec 2025–Jan 2026) | 3+1 | SCDM | ◑ high-risk | ◑ SCDM/high-risk | ✔ 12–15m | SCDM | ✘ | SCDM | ◑ high-risk only (CDC); AAP still universal | State school/daycare mandates; exemptions vary |
| Canada (provincial) | 2, 4, 6, 12, 18m | 3+1 (penta/hexa) | ◑ most provinces infant HepB in hexa, not birth | 2+1 (PCV15/20) | ✔ | ✘ (risk) | ✔ C/ACWY 12m | ✔ | ◑ some | ◑ (Indigenous communities, some) | ✔ | Nirsevimab ✔ universal in Quebec, Ontario; others vary | Ontario/NB school laws with exemptions |
| France | 2, 3*, 4, 6, 11, 12, 16–18m | 2+1 hexa (2, 4, 11m) | ◑ (HepB in hexa) | 2+1 | ✔ (since 2022) | ✔ (mandatory from 2025) | ✔ ACWY 6 & 12m | ✘ | ✘ | ◑ high-risk/Île-de-France, Guyana | ✘ | Nirsevimab ✔ + maternal | Mandatory (11 vaccines) |
| Germany | 2, 3*, 4, 11, 12–15m | 2+1 hexa | ◑ | 2+1 | ✔ | ✔ (since 2024) | ✔ C 12m | ✔ MMR+V 11 & 15m | ✘ | ✘ | ✘ | Nirsevimab ✔ | Measles law (daycare/school; fines) |
| Italy | 3, 5, 11–13, 13–15m | 2+1 hexa | ◑ | 2+1 | ✔ | ✔ | ✔ | ✔ MMRV | ✘ | ✘ | ✔ | Nirsevimab ✔ | Mandatory (10 vaccines) |
| Spain | 2, 4, 11, 12, 15m | 2+1 hexa | ◑ | 2+1 | ✔ | ✔ | ✔ C 4m, ACWY 12m | ✔ 15m | ✘ (✔ Ceuta/Melilla) | ✘ (Basque historic) | ✔ | Nirsevimab ✔ | Voluntary |
| Portugal | birth, 2, 4, 6, 12, 18m | 3+1 hexa | ✔ universal | 2+1 | ? | ✔ | ✔ | ✘ | ✘ | ◑ (since 2016) | ✘ | Nirsevimab ✔ | Voluntary |
| Netherlands | 3, 5, 11, 14m | 2+1 hexa | ◑ | 2+1 | ✔ (2024) | ✘ | ✔ ACWY 14m | ✘ | ✘ | ◑ | ✘ | Nirsevimab ✔ (2025/26) | Voluntary |
| Belgium | 8, 12, 16wk, 12–15m | 3+1 hexa | ◑ | 2+1 | ✔ | ✘ | ✔ | ✘ | ✘ | ✘ | ✘ | Nirsevimab ✔ + maternal | Polio only mandatory |
| Denmark | 3, 5, 12, 15m | 2+1 penta | ◑ (risk only) | 2+1 | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ (LAIV 2–6y) | ? | Voluntary |
| Sweden | 6wk(rota), 3, 5, 12, 18m | 2+1 hexa | ◑ | 2+1 | ✔ | ✘ | ✘ | ✘ | ✘ | ◑ (risk) | ✘ | Nirsevimab ✔ (2025/26) | Voluntary |
| Norway | 6wk(rota), 3, 5, 12, 15m | 2+1 hexa | ◑ | 2+1 | ✔ | ✘ | ✘ | ✘ | ✘ | ◑ | ✘ | ? | Voluntary |
| Finland | 2, 3, 5, 12, 18m | 2+1 penta | ◑ (risk only) | 2+1 | ✔ (3 doses) | ✘ | ✘ | ✘ | ✘ | ◑ | ✔ | Nirsevimab ✔ | Voluntary |
| Iceland | 3, 5, 6, 8, 12, 18m | 2+1 | ◑ (risk only) | 2+1 | ? | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ | Nirsevimab ✔ (2025/26) | Voluntary |
| Poland | birth, 2, 3–4, 5–6, 13–18m | 3+1 | ✔ universal | 2+1 | ✔ | ✘ | ✘ | ◑ | ✘ | ✔ at birth (mandatory) | ✘ | Maternal only ✔ | Mandatory (fines) |
| Hungary | 2, 3, 4, 13–18m | 3+1 hexa | ◑ | 2+1 | ? | ✘ | ✘ | ✔ (mandatory) | ✘ | ✔ at birth | ✘ | ? | Mandatory |
| Czechia / Slovakia | ~2, 4, 11–13m | 2+1 hexa | ◑ | 2+1 | ? | ? | ? | ✘ | ✘ | ✘ (ended 2010/2012) | ✘ | ✔ (CZ) | Mandatory |
| Baltics (LT, LV, EE) | birth onward | 3+1 | ✔ LT (universal) | 2+1 | ✔ | ? | ✘ | ✔ LV | ✘ | ✔ at birth | ✘ | ✔ (LT, LV) | Latvia mandatory |
| Japan | 2, 3, 4, 5–8, 12–18m | 3+1 penta (DPT-IPV-Hib since Apr 2024) | ✘ (universal HepB from 2m) | 3+1 PCV15/20 | ✔ | ✘ | ✘ | ✔ 2 doses | ✘ | ✔ (5–8m) | ✘ (voluntary) | ✘ | Voluntary (“duty to endeavour”) |
| South Korea | birth, 1, 2, 4, 6, 12–23m | 3+1 | ✔ universal | 3+1 | ✔ (NIP 2023) | ✘ | ✘ | ✔ 1 dose | ✔ 12–23m | ✔ intradermal <4wk | ✔ | ? | Voluntary |
| Singapore | birth, 2, 4, 6, 12, 15, 18m | 3+1 (6-in-1/5-in-1) | ✔ universal | 2+1 PCV13 (4, 6, 12m) | ✘ (optional) | ✘ | ✘ | ✔ 12 & 15m | ✘ | ✔ at birth | ✔ | ? | Diphtheria and measles compulsory by law |
| Israel | birth, 1, 2, 4, 6, 12, 18, 24m | 3+1 | ✔ universal | 2+1 | ✔ (3 doses) | ✘ | ✘ | ✔ MMRV 12m | ✔ 18 & 24m | ✘ (targeted) | ✔ | Nirsevimab at birth (most babies) | Voluntary |
| Türkiye | birth, 1, 2, 4, 6, 12, 18, 24m | 3+1 (+OPV) | ✔ universal | 2+1 | ✘ | ✘ | ✘ | ✔ 12m | ✔ 18 & 24m | ✔ 2m | ✘ | ✘ | State-delivered; effectively expected |
| Mexico | birth, 2, 4, 6, 12, 18m | 3+1 hexa | ✔ universal | 2+1 | ✔ | ✘ | ✘ | ✘ | ✘ | ✔ at birth | ✔ | ✘ | Legal duty, weak enforcement |
| Chile | birth, 2, 4, 6, 12, 18m | 3+1 hexa | ✔ | 2+1 | ? | ✘ | ✔ ACWY 12m | ✔ 18m | ✔ 18m | ✔ at birth | ✔ | Nirsevimab universal (since 2024) | Mandatory programme vaccines |
| Colombia | birth, 2, 4, 6, 12, 18m | 3+1 | ✔ | 2+1 | ✔ | ✘ | ✘ | ✔ 12m | ✔ 12m | ✔ at birth | ✔ (6–23m) | ? | Programme-mandated |
| Costa Rica | birth, 2, 4, 6, 15, 18m | 3+1 hexa | ✔ | 2+1 | ✔ | ✘ | ✘ | ✔ | ? | ✔ at birth | ✔ | ? | Compulsory by law |